Diabetes medicines taken before hospital stays for pneumonia in adults with type 2 diabetes
Looks back at GLP-1 and SGLT2 medicines in adults with diabetes hospitalized for pneumonia.
Plain-language title generated from the registry record
Registry title: Preadmission GLP-1 Receptor Agonist Plus SGLT2 Inhibitor Use and Early Outcomes After Pneumonia Hospitalization in Adults With Type 2 Diabetes
Key facts
- Where
- Taichung, TaiwanSee the site
Where in Taiwan
- Chung Shan Medical University HospitalTaichung, TaiwanNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Chung Shan Medical University
- Trial code
- NCT07708610
- Record updated
- 16 July 2026
- Original description
This retrospective observational target-trial emulation uses electronic health record data from the TriNetX US Collaborative Network to compare preadmission glucose-lowering treatment strategies in adults with type 2 diabetes hospitalized with pneumonia. Time zero is the date of the index pneumonia admission. The study compares patients with evidence of prescriptions for both a GLP-1 receptor agonist and an SGLT2 inhibitor in the year before admission with patients prescribed a GLP-1 receptor agonist alone, an SGLT2 inhibitor alone, or usual care. Usual care includes metformin, sulfonylureas, or DPP-4 inhibitors without either study class. The primary outcome is a composite of all-cause death, invasive mechanical ventilation, or renal replacement therapy within 30 days of admission, with the individual components and 12-month mortality, major adverse cardiovascular events, and major adverse kidney events also evaluated. Propensity-score methods are used to reduce bias from nonrandom treatment selection.Read full original descriptionShow less
Preadmission GLP-1 Receptor Agonist Plus SGLT2 Inhibitor Use and Early Outcomes After Pneumonia Hospitalization in Adults With Type 2 Diabetes: A Target Trial Emulation
This retrospective observational target-trial emulation uses electronic health record data from the TriNetX US Collaborative Network to compare preadmission glucose-lowering treatment strategies in adults with type 2 diabetes hospitalized with pneumonia. Time zero is the date of the index pneumonia admission. The study compares patients with evidence of prescriptions for both a GLP-1 receptor agonist and an SGLT2 inhibitor in the year before admission with patients prescribed a GLP-1 receptor agonist alone, an SGLT2 inhibitor alone, or usual care. Usual care includes metformin, sulfonylureas, or DPP-4 inhibitors without either study class. The primary outcome is a composite of all-cause death, invasive mechanical ventilation, or renal replacement therapy within 30 days of admission, with the individual components and 12-month mortality, major adverse cardiovascular events, and major adverse kidney events also evaluated. Propensity-score methods are used to reduce bias from nonrandom treatment selection.
Inclusion: Adults aged 18 years or older; Type 2 diabetes mellitus; Hospitalization with pneumonia during the study period, serving as the index admission; Prescription of a GLP-1 receptor agonist, an SGLT2 inhibitor, or usual-care glucose-lowering therapy in the year before the index admission; No GLP-1 receptor agonist or SGLT2 inhibitor prescription in the 6 months before the first qualifying prescription.
Exclusion: Bariatric surgery; Solid-organ transplantation; Pneumonia hospitalization, invasive mechanical ventilation, or renal replacement therapy in the year before the index admission; Acute cardiovascular event in the 6 months before the index admission; Type 1 diabetes mellitus, or other specified diabetes types that are not type 2 diabetes; Human immunodeficiency virus infection; End-stage kidney disease, dialysis dependence, ventilator dependence, or tracheostomy status; Metastatic malignancy, lung cancer, or palliative care; Viral pneumonia, influenza with pneumonia, or COVID-19 around the index admission.